Visa Integrity Risk Program for peptide merchants in 2026
- Visa consolidated its old dispute and fraud monitoring programs into one framework, VAMP, replacing the separate VMM and VDMP regimes through 2025 into 2026.
- The excessive threshold peptide operators must stay under is 0.9% — lower than the old programs, with less room to drift.
- Crossing it brings remediation timelines, fees, and a path to MATCH, so the work is prevention, not appeal.
On this page
A peptide operator got a notice from his acquirer in early 2026 that did not match anything he had read before. He knew the old Visa programs — the ones with the 1% dispute thresholds and the staged warning months. This notice referenced a different framework, a different threshold, and a faster clock. He had not done anything new. The rules had changed underneath him. Visa had consolidated its monitoring programs, lowered the line, and his acquirer was now measuring him against it. He had three months of decent numbers and a ratio sitting at 0.95% — fine under the old regime, over the line under the new one.
This is what changed, why peptide merchants feel it more than most, and what the work actually is. Spoiler: the work is prevention, because once you are in the program the appeal options are thin.
What replaced the old monitoring programs
For years Visa ran dispute and fraud monitoring as separate tracks — the dispute monitoring program and the fraud monitoring program, each with its own thresholds and its own staged enrollment. Through 2025 and into 2026 Visa consolidated these into a single integrity and acceptance-monitoring framework, commonly referenced as VAMP. The old separate programs that peptide operators learned the hard way are being retired in favor of one consolidated measurement.
The practical effect is a single combined view of your account health rather than two scoreboards. For a peptide merchant that means there is no longer a fraud track to pass while quietly failing the dispute track or vice versa. One framework, one line, less room to be half-clean.
The 0.9% threshold and why it bites peptides
The number to memorize is 0.9%. Under the consolidated framework, the excessive dispute ratio threshold sits at 0.9% — below the 1% line many operators still carry in their heads from the old program. Mastercard's comparable excessive-chargeback program still sits at 1.0%, and severe tiers across the networks run roughly 1.8% to 2.0%. So Visa is now the tighter of the two, and peptides feel it first.
Peptides feel it because the category runs hot on disputes for structural reasons: subscription rebills the customer forgot, not-recognized descriptors, product-not-received claims on slow international shipping, and a buyer base that disputes rather than contacts support. None of that is fraud in the criminal sense, but all of it counts toward the ratio. A 0.9% line gives a peptide book far less slack than the old 1% world did.
| Program | Network | Excessive threshold | Severe tier |
|---|---|---|---|
| VAMP (consolidated) | Visa | 0.9% | ~1.8-2.0% |
| ECM | Mastercard | 1.0% | ~1.8-2.0% |
| Old VMM / VDMP | Visa (retired) | 0.9-1.0% | ~1.8%+ |
How the ratio is actually counted
The ratio is disputes in a month divided by transactions, and the details of which disputes count are where operators get surprised. Under the consolidated framework, fraud and non-fraud disputes are measured together rather than on separate tracks, so a clean fraud profile no longer offsets a messy dispute profile. The count also leans on disputes that actually post, which is why winning representment matters — a dispute you successfully fight back is a dispute that does not weigh against you the same way.
One nuance: some dispute resolutions and pre-dispute interventions can keep a complaint from counting against the ratio at all if they happen early enough in the cycle. The tooling for that lives at the acquirer and gateway level, and getting it switched on is part of the prevention work, not an afterthought.
What happens when you cross the line
Crossing 0.9% does not close your account on day one. It enrolls you in a remediation timeline. You get a window — typically a few months — to bring the ratio back under the threshold, during which Visa assesses fees and your acquirer watches closely. Stay over the line through the timeline, or climb into the severe tier, and the outcome escalates toward account termination and a potential MATCH entry under the relevant reason code.
MATCH is the part that outlives the closure. It is operated by Mastercard, carries a five-year retention, and uses 14 reason codes, several of which map directly to excessive disputes. A peptide merchant who rides out a remediation timeline badly does not just lose one account — they inherit a five-year listing that every future acquirer sees at underwriting. That is why the entire game is staying under 0.9%, not arguing your way out after.
The prevention work, concretely
There is no appeal worth building your plan around. The plan is keeping the ratio low, and for peptides the levers are specific:
- Match your billing descriptor to the storefront name so not-recognized disputes drop.
- Fight every winnable dispute with tracking, delivery confirmation, and signed terms — representment that posts a win keeps the ratio down.
- Tune fraud filters so genuine fraud never posts as a dispute in the first place; see filter tuning for peptide stores.
- Make refunds easy and visible so a frustrated customer refunds instead of disputes — a refund does not count toward the ratio; a chargeback does.
- Soften subscription rebills with advance reminder emails so forgotten renewals do not become disputes.
Run these and a healthy peptide book sits comfortably under 0.9% with headroom for a bad week. Skip them and the new threshold catches you faster than the old one ever did.
Where structure helps and where it does not
The consolidated framework measures at the account level, which raises the structure question for multi-brand operators. Separate MIDs isolate a ratio problem to one brand, so a single brand crossing 0.9% does not drag the others into remediation. A parent account concentrates that exposure but consolidates the dispute queue and the representment workflow, which can keep the blended ratio lower if you actually work the queue. Neither structure lowers disputes by itself — that is operational work — but the structure decides how a ratio problem spreads.
We orchestrate the parent-account model for multi-brand peptide operators, sitting on top of the acquirer and gateway with a consolidated dispute queue and per-brand descriptors. We do not process or settle the payment ourselves and we do not make your ratio go down — your fulfillment, descriptors, and representment do that. For a single brand, a specialist ISO plus disciplined dispute work is the right setup and we will say so. See the layer in how it works.
If you run several peptide brands and the new 0.9% line has you worried about how a problem on one brand spreads to the rest, an honest fit check is twelve questions and ends with a straight read on whether a consolidated dispute structure helps your specific book or whether you are better off keeping brands isolated.